Post-procedural/pre-hemostasis intra-arterial XXXX after transradial catheterization: A gender based analysis.

@entity432 @entity1 @entity1242
BACKGROUND: We analyzed the effect of @entity1242 on radial @entity432 (RAO) in @entity1 undergoing transradial catheterization. METHODS: A total of 1706 @entity1 undergoing transradial catheterization were randomized to receive either 500 g intra-arterial @entity1242 or placebo at the end of the radial procedure. We explored the gender-based analysis between @entity1 (n=539) and @entity1 (n=1167). The primary outcome was the incidence of RAO as confirmed by absence of antegrade flow at one day after the transradial procedure evaluated by duplex ultrasound of the radial artery. RESULTS: The use of @entity1242 , as compared with placebo, did not significantly reduce the risk of RAO in @entity1 @entity1 [odds ratio, 0.69; 95% confidence interval (CI), 0.38 to 1.26; P=0.147]. The risk of RAO was higher in @entity1 age <60years as compared with @entity1 age >= 60years [5.6% vs. 3.5%; odds ratio, 2.16; 95% CI, 1.18 to 3.94; P=0.008]. In @entity1 age <60years (n=237), both counter puncture technique and a duration of hemostasis >= 4h were associated with a similar enhanced risk of developing RAO (odds ratio, 3.51; 95% CI, 1.59 to 7.72; P<0.001). CONCLUSIONS: The administration of @entity1242 at the end of a transradial catheterization in @entity1 did not reduce the risk of RAO as determined by ultrasound one day after the radial procedure. Age <60years was associated with a higher risk of RAO compared with age >= 60years in @entity1 . Further strategies to reduce RAO in @entity1 are needed.
